2022
SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
2016
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation period